{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:57:00Z","timestamp":1791327420834,"version":"4.3.1"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0294408","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:28:15Z","timestamp":1700159295000},"page":"e0294408","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry"],"prefix":"10.1371","volume":"18","author":[{"given":"Armin","family":"Abadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shehadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-3539","authenticated-orcid":true,"given":"Donald William","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6648-5109","authenticated-orcid":true,"given":"Juthaporn","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"6","key":"pone.0294408.ref001","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency\u2014causes and approach to diagnosis.","volume":"16","author":"S Srivastava","year":"2016","journal-title":"Clin Med (Lond)."},{"issue":"6","key":"pone.0294408.ref002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"F Dhalla","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"pone.0294408.ref003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies.","volume":"34","author":"V Friman","year":"2016","journal-title":"Hematol Oncol."},{"key":"pone.0294408.ref004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.","volume":"10","author":"SY Patel","year":"2019","journal-title":"Front Immunol."},{"issue":"17","key":"pone.0294408.ref005","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes","volume":"121","author":"SA Parikh","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"pone.0294408.ref006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.","volume":"13","author":"C Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"3","key":"pone.0294408.ref007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","article-title":"Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study","volume":"31","author":"I Quinti","year":"2011","journal-title":"J Clin Immunol"},{"issue":"6","key":"pone.0294408.ref008","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"M Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0294408.ref009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: The correct clinical approach","volume":"52","author":"A Pecoraro","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"pone.0294408.ref010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"IK Na","year":"2019","journal-title":"Eur J Haematol"},{"issue":"9","key":"pone.0294408.ref011","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency\u2014an expert opinion","volume":"12","author":"C Agostini","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"pone.0294408.ref012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"U Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"issue":"2","key":"pone.0294408.ref013","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"S Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"pone.0294408.ref014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review.","volume":"26","author":"T Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"2","key":"pone.0294408.ref015","article-title":"Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence.","volume":"9","author":"I Mahmood","year":"2020","journal-title":"Antibodies (Basel)."},{"issue":"3","key":"pone.0294408.ref016","doi-asserted-by":"crossref","first-page":"e0247717","DOI":"10.1371\/journal.pone.0247717","article-title":"Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.","volume":"16","author":"F Cinetto","year":"2021","journal-title":"PLoS One."},{"issue":"6","key":"pone.0294408.ref017","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"N Compagno","year":"2014","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"pone.0294408.ref018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158 Suppl 1","author":"S Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"pone.0294408.ref019","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/1744666X.2020.1788939","article-title":"Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency","volume":"16","author":"V Patel","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"pone.0294408.ref020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2021-0265","article-title":"Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review.","volume":"14","author":"C Anderson-Smits","year":"2022","journal-title":"Immunotherapy"},{"issue":"4","key":"pone.0294408.ref021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus","volume":"106","author":"S Jolles","year":"2021","journal-title":"Eur J Haematol"},{"issue":"2","key":"pone.0294408.ref022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis","volume":"120","author":"LW Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl 1","key":"pone.0294408.ref023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cei.12510","article-title":"Solid organ transplantation: hypogammaglobulinemia and infectious complications after solid organ transplantation","volume":"178 Suppl 1","author":"DF Florescu","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"pone.0294408.ref024","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.200510-1609OC","article-title":"Immunoglobulin G levels before and after lung transplantation","volume":"173","author":"NH Yip","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0294408.ref025","first-page":"57","article-title":"Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications.","volume":"21","author":"EN Broeders","year":"2008","journal-title":"Transpl Int"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:29:16Z","timestamp":1700159356000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294408"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294408","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}